Since a major restructuring at Five Prime Therapeutics in October that kicked off a wind-down of most of its research and preclinical efforts, the company has been looking to add to its partnerships portfolio.
On Wednesday, South San Francisco-based Five Prime (NASDAQ: FPRX) said it inked one such new deal. The agreement, a license deal with Seattle Genetics (NASDAQ: SGEN) to develop and commercialize anticancer antibody-drug conjugate therapies using monoclonal antibodies developed by Five Prime, brings the biotech $5 million up front.
The deal marks a small win in a tough week for Five Prime. On Tuesday, the biotech… Read more »
UNDERWRITERS AND PARTNERS
